The results showed that inhibition of S100A8 significantly increased the sensitivity of glioma cells to TMZ treatment, which further validated the important role of S100A8 in GBM for therapeutic resistance (Supplementary Fig. S8D). The gene discussed is S100A8; the disease is glioblastoma.